Neumora Therapeutics Inc (NMRA) Stock Price, Quote & News

Company Profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associa...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 760 0900

Website: www.neumoratx.com

Address:

490 Arsenal Way, Suite 200, Watertown, United States

InvestorCG Sep. 8 at 4:30 PM

$NMRA Uhhhhhhhhhhhhhhh, aren't we supposed to go up while talking to institutional investors at all these conferences??!?!??

1 · Reply

InvestorCG Sep. 8 at 1:46 PM

$NMRA wonder how Thursday's conference went. Also conferences today and tomorrow. You'll see volume spike if they were able to effective communicate value here.

0 · Reply

Mr_GA Sep. 6 at 2:32 AM

$NMRA Neumora will be attending this event. https://hcwevents.com/annualconference/#toggle-id-5

0 · Reply

YonDoe Sep. 5 at 8:09 PM

$NMRA heavy 2$ 10/7 flow EOD today

0 · Reply

han649 Sep. 5 at 5:08 PM

$NMRA next yr this will be back to $10+, gonna try to accumulate as many shares as possible in $1S…

2 · Reply

Mr_GA Sep. 5 at 1:27 PM

$NMRA https://archive.fast-edgar.com/20250811/ASLNTG223222IZZ222272ZZZ8UDGZ2H2V272/

0 · Reply

XQuise Sep. 4 at 7:30 PM

$NMRA 🧠👀👈🏻

0 · Reply

InvestorCG Sep. 4 at 3:19 PM

$NMRA wtf today. Need reversal.

1 · Reply

InvestorCG Sep. 3 at 2:31 PM

$NMRA For past week or two, I've noticed a pattern that to me indicates some accumulation. Every big block is a green candle, then followed by a stepdown in price with lower volume. I think the accumulator is trying to buy at best prices possible and is controlling price, not letting it run because they are not done accumulating. Hopefully, this road show yields results!

2 · Reply

YonDoe Sep. 3 at 2:11 AM

$NMRA

0 · Reply

Neumora Therapeutics to Participate in Upcoming Conferences in September

Aug 7, 2025, 2:41 AM EDT - 4 weeks ago

Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 4 weeks ago

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 23, 2025, 7:00 AM EDT - 6 weeks ago

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jul 9, 2025, 7:00 AM EDT - 2 months ago

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

May 12, 2025, 7:18 PM EDT - 4 months ago

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 4 months ago

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 7:00 AM EDT - 4 months ago

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 4, 2025, 4:05 PM EDT - 5 months ago

NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 30, 2025, 4:00 PM EDT - 5 months ago

NMRA Deadline: NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 27, 2025, 5:45 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA

Mar 26, 2025, 2:19 AM EDT - 5 months ago

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 15, 2025, 9:29 AM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics

Mar 13, 2025, 10:19 AM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics

Mar 6, 2025, 12:17 PM EST - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit – NMRA

Mar 4, 2025, 8:30 AM EST - 6 months ago

Neumora Therapeutics to Present at Leerink Global Healthcare Conference

Mar 3, 2025, 11:37 AM EST - 6 months ago

Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 7:00 AM EST - 6 months ago

Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 5:45 AM EST - 6 months ago

Investors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA

Feb 26, 2025, 8:46 PM EST - 6 months ago

Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses

Feb 26, 2025, 1:32 PM EST - 6 months ago

Investors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – NMRA

Feb 20, 2025, 5:41 PM EST - 7 months ago

NMRA Investors are Suing Neumora Therapeutics, Inc.; Contact Robbins LLP for More Information

Feb 19, 2025, 10:08 PM EST - 7 months ago

NMRA REMINDER: Kessler Topaz Meltzer & Check, LLP Urges NMRA Investors with Losses to Contact the Firm

Feb 13, 2025, 7:00 AM EST - 7 months ago

Neumora Therapeutics Announces Leadership Transition

InvestorCG Sep. 8 at 4:30 PM

$NMRA Uhhhhhhhhhhhhhhh, aren't we supposed to go up while talking to institutional investors at all these conferences??!?!??

1 · Reply

InvestorCG Sep. 8 at 1:46 PM

$NMRA wonder how Thursday's conference went. Also conferences today and tomorrow. You'll see volume spike if they were able to effective communicate value here.

0 · Reply

Mr_GA Sep. 6 at 2:32 AM

$NMRA Neumora will be attending this event. https://hcwevents.com/annualconference/#toggle-id-5

0 · Reply

YonDoe Sep. 5 at 8:09 PM

$NMRA heavy 2$ 10/7 flow EOD today

0 · Reply

han649 Sep. 5 at 5:08 PM

$NMRA next yr this will be back to $10+, gonna try to accumulate as many shares as possible in $1S…

2 · Reply

Mr_GA Sep. 5 at 1:27 PM

$NMRA https://archive.fast-edgar.com/20250811/ASLNTG223222IZZ222272ZZZ8UDGZ2H2V272/

0 · Reply

XQuise Sep. 4 at 7:30 PM

$NMRA 🧠👀👈🏻

0 · Reply

InvestorCG Sep. 4 at 3:19 PM

$NMRA wtf today. Need reversal.

1 · Reply

InvestorCG Sep. 3 at 2:31 PM

2 · Reply

YonDoe Sep. 3 at 2:11 AM

$NMRA

0 · Reply

InvestorCG Sep. 2 at 11:20 AM

$NMRA https://ir.neumoratx.com/news-releases/news-release-details/neumora-therapeutics-participate-upcoming-conferences-september

1 · Reply

YonDoe Aug. 29 at 5:11 PM

Holding calls on all of these right now. $NMRA $NGRV $VFF $GORO .

0 · Reply

Jdsstocks808 Aug. 28 at 10:17 PM

$NMRA patiently waiting at 2.15. Next week 💪🏾💪🏾

0 · Reply

InvestorCG Aug. 28 at 7:56 PM

$NMRA volume is poo poo. Need to ramp this one up.

1 · Reply

han649 Aug. 28 at 1:14 PM

$NMRA hope we don’t go up too fast , I’m not done loading the boat yet. This company worth more than $1B, way undervalued at this price.

1 · Reply

Spk15 Aug. 28 at 11:52 AM

$NMRA seems like above 2 today

1 · Reply

Mr_GA Aug. 28 at 3:45 AM

$NMRA Moving up overnight

0 · Reply

StocksNCash Aug. 27 at 2:57 AM

$NMRA heating up!

0 · Reply

L2Lurker Aug. 26 at 7:56 PM

$GTIM calls is next. I called $NMRA which went over 1000% gainz. Then I called $FTHM which went over 700% gainz yesterday. $GTIM is the next bagger. The calls are calling!

3 · Reply

tazzcrazy Aug. 26 at 6:51 PM

$NMRA Excellent article!

0 · Reply

nepepe Aug. 26 at 3:57 AM

$NMRA sleeper

3 · Reply

InvestorCG Aug. 25 at 4:35 PM

$NMRA zzzzzzzzzzzzz. One of these days this company will surprise us with a PR, or some sort of IR presence.

0 · Reply

Market Cap	272.07M
Revenue (ttm)	0.00
Net Income (ttm)	-243.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.11

Volume	275,700
Avg Vol	1,486,556
Day's Range	N/A - N/A
Shares Out	161.95M
Stochastic %K	26%
Beta	2.91
Analysts	Sell
Price Target	$7.00